Table 2.
Outcomes for people with dementia and COVID-19 receiving antipsychotics compared to historical controls in 2019 with dementia receiving antipsychotics.
| Exposure | Propensity score matched populations (n) | 30-day thromboembolic events | 30-day thromboembolic events OR (95% CI) | 30-day mortality | 30-day mortality OR (95% CI) |
|---|---|---|---|---|---|
| Any antipsychotic | |||||
| 2019 cohort | 8396 | 6.9% | Reference | 5.5% | Reference |
| COVID-19 cohort | 8396 | 9.1% | 1.36 (1.21–1.52) | 10.1% | 1.93 (1.71–2.17) |
| Quetiapine | |||||
| 2019 cohort | 3534 | 6.0% | Reference | 4.3% | Reference |
| COVID-19 cohort | 3534 | 8.3% | 1.42 (1.18–1.70) | 8.9% | 2.18 (1.78–2.66) |
| Haloperidol | |||||
| 2019 cohort | 3216 | 6.9% | Reference | 10.3% | Reference |
| COVID-19 cohort | 3216 | 8.3% | 1.23 (1.02–1.48) | 13.8% | 1.39 (1.20–1.62) |
| Olanzapine | |||||
| 2019 cohort | 1774 | 8.3% | Reference | 7.0% | Reference |
| COVID-19 cohort | 1774 | 7.8% | 0.94 (0.74–1.20) | 9.0% | 1.32 (1.03–1.68) |
| Risperidone | |||||
| 2019 cohort | 1047 | 4.3% | Reference | 3.2% | Reference |
| COVID-19 cohort | 1047 | 6.7% | 1.60 (1.09–2.34) | 7.9% | 2.57 (1.71–3.86) |
COVID-19: coronavirus disease 2019; OR: odds ratio; 95% CI: 95% confidence interval.